Autopsy report · NCT03018067

A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

“Sponsor stopped program\]”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 months before it stopped.
• 60 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Ardelyx

Sponsor type

Industry

Conditions

Hyperkalemia

Interventions

RDX227675; Placebo

Participants

60 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC
  “stopped by sponsor” (82% match in meaning)
• Target Volume Mode Controlled Ventilator in Obesity Hypoventilation Syndrome
  “Stopped by the sponsor” (80% match in meaning)
• Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
  “Sponsor decision to terminate the program” (79% match in meaning)
• Parkinson's Disease G2019S LRRK2 Genetic Testing Program
  “Sponsor stopped the study” (78% match in meaning)
• Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
  “Study was stopped by the Sponsor” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.